Richard Moreau has taken part in many HIV/AIDS-related clinical trials over the years, but this experience was entirely new to him. “You take part in a trial and that is generally the end of it. There is little, if any, follow-up,” he said. “If you happen to remember, and you want to see how it turns out, you try to find what research journal publishes the results. That’s about it.”
If The Wistar Institute was an independent company, it would dwarf many of the biotech start-ups in the area, with one notable difference: junior researchers like Wistar’s postdoctoral fellows — or postdocs, as they’re more commonly called — don’t bring home stock options or high salaries. Instead, they get paid in a different coin of the realm — the chance to build their own research programs while working alongside world-renowned senior scientists.
Just over 10 years ago, in a moment of poetic justice, Pennsylvania passed legislation to establish CURE, the Commonwealth Universal Research Enhancement program, using money from the landmark $200 billion Tobacco Master Settlement Agreement.
Maureen Murphy, Ph.D., already had a lot on her plate when she joined The Wistar Institute in December of 2011. Murphy, a noted expert on the role of the p53 gene in cancer, brought with her a full research agenda (and all of her research staff) from her laboratory at Fox Chase Cancer Center in Philadelphia.
There are few sights more captivating than construction. As I write this letter to you, workers are using “the cruncher” to tear down our old vivarium, and I admit that I find it hard to tear myself away from the view.
Admittedly, it sounds like a dark sci-fi plot, possibly starring Keanu Reeves: “reprogram” treacherous double agents using nanotechnology — synthetic, engineered molecules — designed to silence a specific gene.
Vaccines take advantage of a remarkable ability of our immune system: it can remember viral infections for years, even decades, after they have first been encountered and defeated. While each individual antibody we make lasts only about a month, we retain the means of making that individual antibody for a lifetime, with rare exceptions.
When the Institute’s founder, General Issac J. Wistar, drew up the Deeds of Trust that dictated the Institute’s terms of management, he required that a male heir directly descended from his grand-uncle, Caspar Wistar, M.D., must always be a member of Wistar’s board of trustees.
As a graduate student at the University of Chicago, he was part of one of the first research labs using X-ray crystallography, a process that reveals the three-dimensional structure of molecules, to study how proteins interact with DNA.
The laboratory of Wistar Professor Paul M. Lieberman, Ph.D., has undertaken a historic, groundbreaking project that may change the way doctors treat a variety of human cancers. Historic, because his is the first laboratory in the United States to receive a Seeding Drug Discovery Award from Wellcome Trust, a United Kingdom-based charity.
The Wistar Institute Cancer Center is the recipient of a $100,000 Institutional Research Grant from the American Cancer Society. With these funds, Wistar can offer staff and junior faculty who currently have no national peer-reviewed research grants support in the form of $20,000 over a three-year period as seed funding for pilot projects. The intent is to help those in the early stages of their careers initiate cancer research projects so they can obtain preliminary results that will enable them to compete successfully for national research grants.
Bruce and Judi Goodman are not only generous contributors to The Wistar Institute; they also put a great deal of thought into their gifts, both present and future. The Goodmans, owners of Jenkintown-based Goodman Properties, came to Wistar offering to make the Institute the beneficiary of a significant life insurance policy. Since then, they have become advocates for using life insurance policies as a means of planned giving.
From Princess Madeline of Sweden to Queen Latifah, he designs for both royalty and those who just want to feel like royalty. Carmen Marc Valvo, whose couture creations are synonymous with glamour and celebrity, is one of the most sought-after fashion designers in the world.
During this spring’s quarterly board meeting, The Wistar Institute proudly announced the election of Helen P. Pudlin, Esq. as chair of the Institute’s board of trustees.
Pudlin, executive vice president and general counsel of The PNC Financial Services Group, is the 18th chair of the board and the first woman to hold the position since the independent biomedical research institute was founded in 1892.